VolitionRx Limited (NYSE American: VNRX) is drawing attention to the expanding body of clinical and scientific evidence that supports its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the test's potential in clinical settings.
Multiple studies have demonstrated that Volition's Nu.Q H3.1 test can effectively distinguish sepsis from non-infectious inflammation. The test also correlates with disease severity and provides strong prognostic value for outcomes including organ failure and mortality. This growing evidence base is crucial, as sepsis remains a leading cause of death worldwide, and early detection is key to improving patient outcomes.
According to the company, most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and diverse patient populations. This consistency lends credibility to the assay's potential as a reliable diagnostic tool.
Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management. This could inform future therapeutic strategies, moving beyond a one-size-fits-all approach to more tailored interventions.
The company's Nu.Q NETs technology targets NETosis, a process involved in the immune response that can become dysregulated in sepsis. By measuring specific biomarkers, the test aims to provide clinicians with actionable information to guide treatment decisions.
Volition is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and NETosis-associated diseases like sepsis.
For more information about Volition and its Nu.Q technology, visit the company's website at https://volition.com/.
To view the full press release, visit https://ibn.fm/2IH3m.
